GLMD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Tel Aviv, Israel. The company went public in March 2014 and focuses exclusively on developing therapeutics for liver diseases. Galmed is currently in advanced clinical trials with its lead drug candidate Aramchol, targeting non-alcoholic steatohepatitis (NASH), a serious liver condition affecting millions worldwide. As a pre-revenue biotech company, Galmed represents the high-risk, high-reward nature of pharmaceutical development, where success depends on navigating complex clinical trials and regulatory approval processes.